Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Rating Cut to Strong Sell at Wall Street Zen

Arrowhead Pharmaceuticals (NASDAQ:ARWR) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “strong sell” rating in a report released on Saturday, Wall Street Zen reports.

ARWR has been the topic of a number of other research reports. HC Wainwright restated a “buy” rating and set a $120.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Thursday, October 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Monday, August 17th. Piper Sandler reiterated an “overweight” rating and set a $126.00 price target (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research report on Thursday, July 23rd. Morgan Stanley lifted their price objective on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Finally, Stifel Nicolaus cut their target price on Arrowhead Pharmaceuticals from $104.00 to $96.00 and set a “buy” rating for the company in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $98.93.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ:ARWR opened at $47.78 on Friday. The company’s 50 day moving average price is $63.32 and its two-hundred day moving average price is $71.00. Arrowhead Pharmaceuticals has a 12-month low of $37.06 and a 12-month high of $95.49. The firm has a market cap of $6.73 billion, a PE ratio of -9.35 and a beta of 1.34. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Michael Perry sold 11,600 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the transaction, the director owned 111,459 shares of the company’s stock, valued at $9,730,370.70. This represents a 9.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Adeoye Olukotun sold 2,000 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the completion of the transaction, the director owned 31,600 shares of the company’s stock, valued at $2,747,936. This represents a 5.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 3.60% of the stock is owned by corporate insiders.

Institutional Trading of Arrowhead Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Optiver Holding B.V. boosted its position in shares of Arrowhead Pharmaceuticals by 83.8% during the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 186 shares in the last quarter. Versant Capital Management Inc grew its position in shares of Arrowhead Pharmaceuticals by 285.1% during the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after buying an additional 248 shares during the period. Carolina Wealth Advisors LLC increased its stake in shares of Arrowhead Pharmaceuticals by 80.6% in the 2nd quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 154 shares in the last quarter. Persistent Asset Partners Ltd bought a new stake in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at $39,000. Finally, Heritage Family Offices LLP bought a new stake in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at $40,000. Institutional investors own 62.61% of the company’s stock.

Key Headlines Impacting Arrowhead Pharmaceuticals

These are some of the ARWR headlines that stood out recently:

• Positive Sentiment: Royal Bank of Canada reaffirmed its “outperform” rating and $100 price target, signaling continued analyst confidence in Arrowhead’s potential. Royal Bank of Canada rating
• Neutral Sentiment: Stifel Nicolaus kept its “buy” rating but lowered its price target to $96 from $104, reflecting a more cautious valuation while retaining a bullish view. Stifel Nicolaus rating
• Negative Sentiment: Arrowhead reported a full-year fiscal 2026 loss of $5.11 per share. An earnings analysis also highlights the challenge of making costly R&D pay off as market sentiment toward RNA interference (RNAi) turns more skeptical. Full-year earnings results Earnings analysis

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues. The company’s research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.